



Our Ref. No. TPIP021

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:  
Inventor(s) : Hua Tang et al.  
Serial No. : 10/695,291  
Filed : October 28, 2003  
Title : PROPOFOL WITH CYSTEINE

## **Request for Correction of Filing Receipt**

**Attention: Initial Patent Examination Division**

Assistant Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313

Dear Sir:

In reviewing the FILING RECEIPT mailed on March 19, 2004 in connection with the above-identified application, it was discovered that the city of the third inventor is spelled incorrectly. A copy of the filing receipt showing the requested corrections in red is attached.

Please correct the filing receipt to list the third inventors as:

Orn Almarsson, Shrewsbury, MA;

Since this a PTO error, applicants believe no fee is due. However, the Commissioner is hereby authorized to credit any overpayment or charge our Deposit Account No. 50-2626 for any fee deficiency that may be due.

Also, please direct any correspondence in connection with the above-identified application to the undersigned.

Respectfully submitted,

TRANSFORM PHARMACEUTICALS, INC.

Date: May 4, 2004

  
Paul Burgess  
Reg. No. 53,852


29 Hartwell Avenue  
Lexington, MA 02421

Telephone: (781) 674-7816  
Facsimile: (781) 863-8914

**Certificate of Mailing**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, PO Box 1450, Alexandria, VA 22313, on May 10, 2004.

Jacquie M. Vo  
*Typed or Printed Name*

  
*Jacquie M. Vo*  
*Signature*




UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/695,291	10/28/2003	1614	385	TPIP021		17	3

Transform Pharmaceuticals, Inc.  
29 Hartwell Avenue  
Lexington, MA 02421



CONFIRMATION NO. 3947  
FILING RECEIPT



\*OC000000012148011\*

Date Mailed: 03/19/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Hua Tang, Cambridge, MA;  
Hongming Chen, Acton, MA;  
Orn Almarsson, Shrewsbury, MA; Shrewsbury, MA;

**Assignment For Published Patent Application**

Transform Pharmaceuticals, Inc., Lexington, MA;

**Domestic Priority data as claimed by applicant**

This appln claims benefit of 60/422,196 10/29/2002

**Foreign Applications**

If Required, Foreign Filing License Granted: 03/19/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

**Title**

Propofol with cysteine

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).